Woodley Farra Manion Portfolio Management Inc. Sells 232,588 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Woodley Farra Manion Portfolio Management Inc. decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 98.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,563 shares of the medical research company's stock after selling 232,588 shares during the period. Woodley Farra Manion Portfolio Management Inc.'s holdings in Charles River Laboratories International were worth $473,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of CRL. Versant Capital Management Inc increased its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. lifted its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Assetmark Inc. boosted its stake in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after acquiring an additional 173 shares during the period. ORG Wealth Partners LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth approximately $59,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In related news, CEO James C. Foster acquired 6,075 shares of the stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Up 1.2 %

Shares of NYSE CRL traded up $2.00 during mid-day trading on Thursday, reaching $169.55. The company had a trading volume of 1,171,334 shares, compared to its average volume of 696,367. The stock has a market capitalization of $8.67 billion, a PE ratio of 1,130.31, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock's 50 day moving average is $169.69 and its 200-day moving average is $186.19.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.46 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CRL shares. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their target price for the stock from $155.00 to $175.00 in a research report on Tuesday. Barclays dropped their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 18th. JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. The Goldman Sachs Group dropped their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Finally, TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $198.36.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).